Gary P Kobinger

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. pmc Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
  2. pmc A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, Canada
    PLoS ONE 5:e15301. 2010
  3. pmc Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
    PLoS ONE 3:e3548. 2008
  4. doi request reprint Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 204:200-8. 2011
  5. doi request reprint Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    J Infect Dis 201:1000-6. 2010
  6. ncbi request reprint Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S413-20. 2007
  7. ncbi request reprint Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Vaccine 25:5220-31. 2007
  8. doi request reprint Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, MB, Canada
    Vaccine 30:626-36. 2012
  9. ncbi request reprint Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, University of Manitoba, Winnipeg, Canada
    Virology 346:394-401. 2006
  10. doi request reprint Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Vaccine 27:3083-9. 2009

Collaborators

Detail Information

Publications25

  1. pmc Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5308. 2009
    ..The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector...
  2. pmc A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, Canada
    PLoS ONE 5:e15301. 2010
    ..Overall, PAV3-based vector is capable of mediating swift, strong immune responses and offer a promising alternative to AdHu5...
  3. pmc Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
    PLoS ONE 3:e3548. 2008
    ....
  4. doi request reprint Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 204:200-8. 2011
    ..See the editorial commentary by Bausch, on pages 179-81.)..
  5. doi request reprint Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    J Infect Dis 201:1000-6. 2010
    ..The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine...
  6. ncbi request reprint Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S413-20. 2007
    ....
  7. ncbi request reprint Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Vaccine 25:5220-31. 2007
    ..These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection...
  8. doi request reprint Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection
    Ami Patel
    National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, Winnipeg, MB, Canada
    Vaccine 30:626-36. 2012
    ..Overall, the data suggest that co-administering certain H5N1 antigens offer better or comparable protection to HA alone, however, combining extra antigens may be unnecessary and lead to unfavourable immune responses...
  9. ncbi request reprint Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, University of Manitoba, Winnipeg, Canada
    Virology 346:394-401. 2006
    ..These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier...
  10. doi request reprint Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Vaccine 27:3083-9. 2009
    ..This study emphasizes the need to evaluate the relationship between both arms of the adaptive immune responses in regards to protective efficacy against influenza virus...
  11. ncbi request reprint Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells
    Gary P Kobinger
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 3R2
    Hum Gene Ther 18:413-22. 2007
    ..Spike-pseudotyped HIV-based vector is a novel lung-directed gene transfer vehicle that holds promise for the treatment of genetic lung diseases such as cystic fibrosis or alpha(1)-antitrypsin deficiency...
  12. doi request reprint Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs
    Jason S Richardson
    Special Pathogens Department, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1032-42. 2011
    ..The humoral immune response was assayed to determine the effect of vaccine delivery route and preexisting immunity...
  13. pmc Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus
    David Safronetz
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 83:7285-95. 2009
    ..These observations set the stage for a more detailed characterization of the types of immunity required to protect humans from hantavirus infections...
  14. pmc Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Rep 3:3365. 2013
    ..The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure. ..
  15. doi request reprint mAbs and Ad-Vectored IFN-╬▒ therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 5:207ra143. 2013
    ..This study describes conditions capable of saving 100% of EBOV-infected NHPs when initiated after the presence of detectable viremia along with symptoms. ..
  16. pmc Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure...
  17. pmc Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 87:7754-7. 2013
    ..p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i...
  18. pmc A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
    Jin Huk Choi
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States
    Mol Pharm 9:156-67. 2012
    ..SL immunization also reduced systemic anti-Ad5 T and B cell responses in naive mice and those with PEI, suggesting that secondary immunizations could be highly effective for both populations...
  19. pmc Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates
    Jason S Richardson
    Special Pathogens Department, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Virol 87:3668-77. 2013
    ....
  20. ncbi request reprint Recent advances in Ebolavirus vaccine development
    Jason S Richardson
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    Hum Vaccin 6:439-49. 2010
    ..Post-exposure protection is particularly important in outbreak and biodefense settings, as well as clinical and laboratory settings in the case of accidental exposure...
  21. pmc Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway
    James E Strong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 3R2
    Proc Natl Acad Sci U S A 105:17982-7. 2008
    ....
  22. pmc PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum
    Maria A Croyle
    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin Austin, Texas 78712, USA
    J Virol 78:912-21. 2004
    ....
  23. pmc Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines
    Ami Patel
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    PLoS ONE 7:e43802. 2012
    ..Overall, the data suggest that rare or non-existent oligopeptides can be developed as immunomodulators and supports the further evaluation of some 5-mer peptides as potential vaccine adjuvants...
  24. ncbi request reprint Characterization of host immune responses in Ebola virus infections
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street Winnipeg, MB, R3E 3R2 Canada
    Expert Rev Clin Immunol 10:781-90. 2014
    ..This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics...
  25. doi request reprint Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:138ra81. 2012
    ..These data highlight the important role of antibodies to control EBOV replication in vivo, and support the use of mAbs against a severe filovirus infection...